Rare Diseases & Orphan Drug

E.coli is one of the main cause of nosocomial infection in humans. E.coli being one of the common organism causing hospital acquired infections exhibits ESBL production Causing resistant to Beta lactam group of drugs resulting in limited treatment options. Hence, this study was done to know the resistance pattern in E.coli and their virulence factors. Materials and Methods: Samples (urine, pus, sputum) were collected & processed as per standard protocols E.coli were isolated. Antibiogram done as per CLSI guidelines. ESBL & MBL screening done, Biofi lm formation of E.coli was studied in correlation to antibiotic resistance. Result: 235 E.coli were isolated from various clinical samples. Out of 235, 148 (62.97%) showed resistance to ceft azidime & cefatoxime, 53 (22.55%) were ESBL producers, 19 (8.8%) showed resistance to imipenem, 32 (1.27%) were MBL producer. E.coli were resistant to nalidixic acid, 119 (50.6%) followed by Cotrimoxazole 98(41.7%), Ciprofl oxacin resistance was 135 (57.6%) and MIC ranged from 8- 64 μg/ml. Among 235 E.coli isolates 169 (46.38%) were MDR of which 29 (12.34%) were strong biofi lm producers.

Conclusion: Th is study highlights that all isolated ESBL producers were resistant to 3rd Gen. cephalosporins. Th is increase in resistance to number of commonly used antibiotics shows the emerging drug resistance. In view of this, ESBL testing and MBL screening should be made as a routine testing which will help in the shuffl ing of antibiotics and for proper treatment and to prevent further development of bacterial drug resistance